Altimmune to Participate in Stifel Cardiometabolic Forum
Altimmune Inc ALT
$3.06
▲ +0.66%
(+$0.02)
🔥 High Short Interest
Open
$3.05
Prev Close
$3.04
Day Range
$3.00 – $3.11
52W Range
$2.56 – $6.44
Market Cap
$595.22M
Beta
0.06
EPS (TTM)
$-0.78
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2005-10-06 |
| Shares Out. | 194,470,000 |
| Website | altimmune.com/ ↗ |
| Phone | 12406541450 |
| Employees | 57 |
| Revenue | $0 |
| Gross Profit | $0 |
| Net Income | -$22.8M |
| Free Cash Flow | -$76.6M |
| Total Assets | $527.2M |
| Total Liabilities | $53.0M |
| Equity | $474.2M |
About Altimmune Inc
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
Altimmune Inc is a publicly traded company under the ticker symbol ALT on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
15 analysts (2026-09-01)